KR20200074085A - 고칼륨혈증 치료를 위한 글리시레틴산 유도체 - Google Patents

고칼륨혈증 치료를 위한 글리시레틴산 유도체 Download PDF

Info

Publication number
KR20200074085A
KR20200074085A KR1020207006241A KR20207006241A KR20200074085A KR 20200074085 A KR20200074085 A KR 20200074085A KR 1020207006241 A KR1020207006241 A KR 1020207006241A KR 20207006241 A KR20207006241 A KR 20207006241A KR 20200074085 A KR20200074085 A KR 20200074085A
Authority
KR
South Korea
Prior art keywords
ethoxy
oxy
methyl
dihydro
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207006241A
Other languages
English (en)
Korean (ko)
Inventor
개리 뤼어
딘 드래골리
마이클 리드베터
타오 첸
제이슨 루이스
Original Assignee
알데릭스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알데릭스, 인코포레이티드 filed Critical 알데릭스, 인코포레이티드
Priority to KR1020247031867A priority Critical patent/KR20240144491A/ko
Publication of KR20200074085A publication Critical patent/KR20200074085A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B3/00—Simple or compound lenses
    • G02B3/0006—Arrays
    • G02B3/0037—Arrays characterized by the distribution or form of lenses
    • G02B3/0056—Arrays characterized by the distribution or form of lenses arranged along two different directions in a plane, e.g. honeycomb arrangement of lenses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B5/00—Optical elements other than lenses
    • G02B5/02—Diffusing elements; Afocal elements
    • G02B5/0205—Diffusing elements; Afocal elements characterised by the diffusing properties
    • G02B5/021—Diffusing elements; Afocal elements characterised by the diffusing properties the diffusion taking place at the element's surface, e.g. by means of surface roughening or microprismatic structures
    • G—PHYSICS
    • G02—OPTICS
    • G02F—OPTICAL DEVICES OR ARRANGEMENTS FOR THE CONTROL OF LIGHT BY MODIFICATION OF THE OPTICAL PROPERTIES OF THE MEDIA OF THE ELEMENTS INVOLVED THEREIN; NON-LINEAR OPTICS; FREQUENCY-CHANGING OF LIGHT; OPTICAL LOGIC ELEMENTS; OPTICAL ANALOGUE/DIGITAL CONVERTERS
    • G02F1/00—Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics
    • G02F1/01—Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour 
    • G02F1/13—Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour  based on liquid crystals, e.g. single liquid crystal display cells
    • G02F1/133—Constructional arrangements; Operation of liquid crystal cells; Circuit arrangements
    • G02F1/1333—Constructional arrangements; Manufacturing methods
    • G02F1/1335—Structural association of cells with optical devices, e.g. polarisers or reflectors
    • G02F1/133524—Light-guides, e.g. fibre-optic bundles, louvered or jalousie light-guides
    • G—PHYSICS
    • G02—OPTICS
    • G02F—OPTICAL DEVICES OR ARRANGEMENTS FOR THE CONTROL OF LIGHT BY MODIFICATION OF THE OPTICAL PROPERTIES OF THE MEDIA OF THE ELEMENTS INVOLVED THEREIN; NON-LINEAR OPTICS; FREQUENCY-CHANGING OF LIGHT; OPTICAL LOGIC ELEMENTS; OPTICAL ANALOGUE/DIGITAL CONVERTERS
    • G02F1/00—Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics
    • G02F1/01—Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour 
    • G02F1/13—Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour  based on liquid crystals, e.g. single liquid crystal display cells
    • G02F1/133—Constructional arrangements; Operation of liquid crystal cells; Circuit arrangements
    • G02F1/1333—Constructional arrangements; Manufacturing methods
    • G02F1/1335—Structural association of cells with optical devices, e.g. polarisers or reflectors
    • G02F1/133526—Lenses, e.g. microlenses or Fresnel lenses
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B2207/00—Coding scheme for general features or characteristics of optical elements and systems of subclass G02B, but not including elements and systems which would be classified in G02B6/00 and subgroups
    • G02B2207/123—Optical louvre elements, e.g. for directional light blocking

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nonlinear Science (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mathematical Physics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020207006241A 2017-08-04 2018-08-06 고칼륨혈증 치료를 위한 글리시레틴산 유도체 Ceased KR20200074085A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247031867A KR20240144491A (ko) 2017-08-04 2018-08-06 고칼륨혈증 치료를 위한 글리시레틴산 유도체

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762541095P 2017-08-04 2017-08-04
US62/541,095 2017-08-04
PCT/US2018/045421 WO2019060051A1 (en) 2017-08-04 2018-08-06 GLYCYRRHETINIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERKALIEMIA

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247031867A Division KR20240144491A (ko) 2017-08-04 2018-08-06 고칼륨혈증 치료를 위한 글리시레틴산 유도체

Publications (1)

Publication Number Publication Date
KR20200074085A true KR20200074085A (ko) 2020-06-24

Family

ID=63364189

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207006241A Ceased KR20200074085A (ko) 2017-08-04 2018-08-06 고칼륨혈증 치료를 위한 글리시레틴산 유도체
KR1020247031867A Pending KR20240144491A (ko) 2017-08-04 2018-08-06 고칼륨혈증 치료를 위한 글리시레틴산 유도체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247031867A Pending KR20240144491A (ko) 2017-08-04 2018-08-06 고칼륨혈증 치료를 위한 글리시레틴산 유도체

Country Status (17)

Country Link
US (3) US11768319B2 (https=)
EP (2) EP3661945B1 (https=)
JP (3) JP7281446B2 (https=)
KR (2) KR20200074085A (https=)
CN (2) CN118440135A (https=)
AU (3) AU2018335130B2 (https=)
BR (1) BR112020002322A2 (https=)
CA (1) CA3071992A1 (https=)
EA (1) EA202090438A1 (https=)
IL (3) IL318937A (https=)
MA (1) MA49761A (https=)
MX (2) MX2020001412A (https=)
PH (1) PH12020500432A1 (https=)
SG (1) SG11202000950TA (https=)
UA (1) UA126584C2 (https=)
WO (1) WO2019060051A1 (https=)
ZA (2) ZA202001352B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220002866A (ko) * 2019-02-07 2022-01-07 알데릭스, 인코포레이티드 고칼륨혈증 치료에 사용하기 위한 글리시레틴산 유도체

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111018938B (zh) * 2019-12-10 2021-05-25 中国人民解放军第二军医大学 一种五环三萜类甘草次酸衍生物及制备方法与应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714880A1 (de) 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
US5519008A (en) * 1992-09-10 1996-05-21 Glycomed Incorporated Derivatives of triterpenoid acids as inhibitors of cell-adhesion molecules ELAM-1 (E-selectin) and LECAM-1 (L-selectin)
DK0612723T3 (da) 1993-02-20 1998-03-30 Hoechst Ag Substituerede benzoylguanidiner, fremgangsmåde til fremstilling, deres anvendelse som lægemiddel, som inhibitor af den cellulære Na+/H+-udbytning eller som diagnostikum samt lægemiddel med indhold deraf
IL109570A0 (en) 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
DE19518796A1 (de) 1995-05-22 1996-11-28 Hoechst Ag Fluorphenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19548812A1 (de) 1995-12-27 1997-07-03 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation
DE19633966A1 (de) 1996-08-22 1998-02-26 Hoechst Ag Phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
JP4166433B2 (ja) * 1997-09-11 2008-10-15 第一製薬株式会社 ホルモン依存性疾患治療剤
DE19945302A1 (de) 1999-09-22 2001-03-29 Merck Patent Gmbh Biphenylderivate als NHE-3-Inhibitoren
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
DE10015248A1 (de) 2000-03-28 2001-10-04 Merck Patent Gmbh Bisamidino-Verbindungen als NHE-3 Inhibitoren
DE10019062A1 (de) 2000-04-18 2001-10-25 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren
DE10043667A1 (de) 2000-09-05 2002-03-14 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline
DE10046993A1 (de) 2000-09-22 2002-04-11 Aventis Pharma Gmbh Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament
DE10063294A1 (de) 2000-12-19 2002-07-04 Aventis Pharma Gmbh Substituierte Heterocyclo-Norbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6736705B2 (en) 2001-04-27 2004-05-18 Hitachi Global Storage Technologies Polishing process for glass or ceramic disks used in disk drive data storage devices
US6911453B2 (en) 2001-12-05 2005-06-28 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
DE10161767A1 (de) 2001-12-15 2003-06-26 Merck Patent Gmbh 2-Guanidino-4-heterocyclyl-chinazoline
US6703405B2 (en) 2001-12-22 2004-03-09 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them
DE10163992A1 (de) 2001-12-24 2003-07-03 Merck Patent Gmbh 4-Aryl-chinazoline
GB0224830D0 (en) * 2002-10-24 2002-12-04 Sterix Ltd Compound
CN1254051C (zh) 2002-10-25 2006-04-26 华为技术有限公司 城域网传输设备中用户数据业务子速率传送方法
US6923466B2 (en) 2002-12-17 2005-08-02 James Tsai Collapsible handcart capable of extending the area of carrier by operating handle
US20050054705A1 (en) 2003-02-04 2005-03-10 Aventis Pharma Deutschland Gmbh N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
WO2004113396A1 (ja) 2003-06-25 2004-12-29 Cmet Inc. 安定性の向上した活性エネルギー線硬化性の光学的立体造形用樹脂組成物
WO2005020612A1 (en) 2003-08-20 2005-03-03 Musky Communications (Proprietary) Limited Telephonic communication
SI1663185T1 (sl) * 2003-09-22 2009-04-30 Onepharm Res & Dev Gmbh Preprečevanje in zdravljenje z vnetjem inducirane in/ali imunsko posredovane izgube kosti
WO2005054705A2 (en) 2003-11-26 2005-06-16 Brian Judd Apparatus for dampening impact vibration in manual tools
US20050244367A1 (en) 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
KR20070038042A (ko) 2004-05-14 2007-04-09 파세코 코퍼레이션 컨테이너 핸들러들을 위한 상황 보고 디바이스들을 만드는장치 및 방법
DE102004046492A1 (de) 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE102004054847A1 (de) 2004-11-13 2006-05-24 Sanofi-Aventis Deutschland Gmbh Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE102005044817A1 (de) 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
MX2008005661A (es) 2005-11-03 2008-12-15 Ilypsa Inc Inhibidores de fosfolipasa, que incluyen inhibidores de fosfolipasa multivalente, y uso de los mismos, que incluyen como inhibidores de fosfolipasa localizadas en el lumen.
US7666898B2 (en) 2005-11-03 2010-02-23 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
GB0604899D0 (en) 2006-03-10 2006-04-19 York Pharma Plc Derivatives of 18-glycyrrhetinic acid
GB0610009D0 (en) 2006-05-19 2006-06-28 Health Prot Agency Culture medium
GB2438389A (en) 2006-05-23 2007-11-28 Gkn Aerospace Transparency Sys Heating system for leading edge of aircraft
SI2384318T1 (en) 2008-12-31 2018-03-30 Ardelyx, Inc. MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT
EP2228380A1 (en) 2009-03-13 2010-09-15 onepharm Research & Development GmbH Novel triterpene derivatives
KR101886467B1 (ko) 2011-01-31 2018-08-07 비브 헬스케어 유케이 (넘버4) 리미티드 Hiv 성숙 억제 활성을 갖는 c-17 및 c-3 변형 트리테르페노이드
US9120839B2 (en) 2012-08-14 2015-09-01 Nexoligo Co., Ltd. Ursolic acid derivative and method for preparing same
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
BR112015003516A2 (pt) 2012-08-21 2017-07-04 Ardelyx Inc compostos e métodos para inibição de antiporte mediado por nhe no tratamento de transtornos associados à retenção de fluido ou sobrecarga de sal e transtornos do trato gastrintestinal
TW201628631A (zh) 2014-12-23 2016-08-16 亞德利克斯公司 用於治療高血鉀症之組合物及方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220002866A (ko) * 2019-02-07 2022-01-07 알데릭스, 인코포레이티드 고칼륨혈증 치료에 사용하기 위한 글리시레틴산 유도체

Also Published As

Publication number Publication date
US20250067907A1 (en) 2025-02-27
IL272443B2 (en) 2024-02-01
IL306058A (en) 2023-11-01
IL272443A (en) 2020-03-31
AU2018335130B2 (en) 2023-02-16
CN118440135A (zh) 2024-08-06
WO2019060051A1 (en) 2019-03-28
JP2025029026A (ja) 2025-03-05
EA202090438A1 (ru) 2020-06-15
MX2023015126A (es) 2024-01-23
US20210163524A1 (en) 2021-06-03
MX2020001412A (es) 2020-08-03
AU2023203009A1 (en) 2023-06-01
BR112020002322A2 (pt) 2020-09-01
PH12020500432A1 (en) 2021-01-25
MA49761A (fr) 2020-06-10
AU2018335130A1 (en) 2020-03-19
KR20240144491A (ko) 2024-10-02
ZA202102866B (en) 2022-10-26
EP3661945A1 (en) 2020-06-10
SG11202000950TA (en) 2020-02-27
CN111386279A (zh) 2020-07-07
CA3071992A1 (en) 2019-03-28
EP3661945B1 (en) 2024-04-03
EP4397366A3 (en) 2024-11-20
US20230273354A1 (en) 2023-08-31
IL318937A (en) 2025-04-01
JP7281446B2 (ja) 2023-05-25
IL272443B1 (en) 2023-10-01
US11768319B2 (en) 2023-09-26
AU2025201400A1 (en) 2025-03-20
JP2023054360A (ja) 2023-04-13
ZA202001352B (en) 2024-10-30
UA126584C2 (uk) 2022-11-02
JP2020529449A (ja) 2020-10-08
EP4397366A2 (en) 2024-07-10

Similar Documents

Publication Publication Date Title
US20250067907A1 (en) Compounds and methods for treating hyperkalemia
US20240209019A1 (en) Compounds and methods for treating hyperkalemia
HK40099473B (en) Glycyrrhetinic acid derivatives for use in treating hyperkalemia
HK40099473A (en) Glycyrrhetinic acid derivatives for use in treating hyperkalemia

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200303

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210806

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231020

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240426

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20231020

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

PA0104 Divisional application for international application